Inhibitor Therapeutics, Inc.
INTI · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $10 | $14 | $36 | $56 |
| - Cash | $6 | $9 | $12 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $5 | $5 | $25 | $57 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | $0 | $0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| Net Income | -$3 | -$3 | $12 | -$0 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.019 | -0.018 | 0.03 | -0.001 |
| % Growth | -10.2% | -158.7% | 2,407.7% | – |
| Operating Cash Flow | -$3 | -$3 | $12 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$3 | -$3 | $12 | -$0 |